Fawad Chaudry, MD
Pulmonary Disease · Oklahoma City, OKNPI 1467656686
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (50.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 88.7% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $40,383, more than ten times the $3,768 reported in 2019. Among pulmonary disease clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $440.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$71K
- Pinnacle Biologics, Inc$4K
- Pulmonx Corporation$2K
- Veran Medical Technologies, Inc.$1K
- Boston Scientific$337
- Johnson & Johnson$262
- plus $1K from 25 others
What the payments were for
- Speaking & faculty fees$18,80023%
- Travel & lodging$13,56917%
- Food & beverage$7,2769%
- Education$40,30050%
- Gifts$1790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 93 | $71,059 |
| Pinnacle Biologics, Inc | 21 | $3,992 |
| Pulmonx Corporation | 18 | $2,041 |
| Veran Medical Technologies, Inc. | 3 | $1,305 |
| Boston Scientific | 6 | $337 |
| Johnson & Johnson(2 entities) | 2 | $262 |
| Olympus America Inc. | 2 | $164 |
| Galvanize Therapeutics, Inc | 2 | $160 |
| Actelion Pharmaceuticals US, Inc. | 4 | $110 |
| Steris Corporation | 2 | $94 |
| Sunovion Pharmaceuticals Inc. | 5 | $74 |
| Gilead | 3 | $68 |
| Pharmacosmos Therapeutics Inc. | 1 | $59 |
| La Jolla Pharmaceutical Company | 2 | $38 |
| Fujifilm Healthcare Americas Corporation | 1 | $35 |
| Eisai Inc. | 1 | $31 |
| AstraZeneca | 2 | $28 |
| United Therapeutics Corporation | 1 | $28 |
| Portola Pharmaceuticals, LLC | 1 | $25 |
| Lilly USA, LLC | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $20 |
| Incyte Corporation | 1 | $20 |
| GSK | 1 | $19 |
| Seagen Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Bayer | 1 | $15 |
| Insmed, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
| Apria Healthcare LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,124 in reported general payments places this provider in the 95th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$332K
- Maroun TawkOklahoma City$62K
- Nathaniel MoultonOklahoma City$28K
- Syed NaqviOklahoma City$15K
- Tarek DernaikaOklahoma City$12K
- Shoab NazirOklahoma City$11K
- Mark GodishOklahoma City$11K
- Mazen ZouwayhedOklahoma City$10K
- Shoaib AhmadOklahoma City$8K
- Azhar KhanOklahoma City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.